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Diabetes mellitus is associated with major cardiovascular
morbidity and mortality, mostly related to diffuse athero-
sclerosis. Although substantial progress has been made in
the prevention and treatment of cardiovascular diseases over
the last two decades, the age and co-morbidity adjusted
death rate among diabetic patients undergoing percutaneous
catheter-based interventions still remain higher than the
general population (1,2). Furthermore, tight glycemic con-
trol, a principal factor in the prevention of microvascular
complication (e.g., retinopathy), was shown to have a
limited effect on the development of macrovascular (e.g.,
atherosclerotic) disease (3,4). The limited therapeutic
achievement in reducing cardiovascular complications
among diabetics, together with the increased worldwide
prevalence of diabetes mellitus, result in overall augmented
fraction of diabetic patients who are likely to undergo
percutaneous coronary intervention (PCI) (5,6).
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The clinical outcome after PCI among patients with
diabetes is less favorable than the outcome among non-
diabetic patients, and it is dominated by higher rate of
restenosis after balloon angioplasty (7,8) and coronary
stenting (9–12). The increased risk of restenosis after
angioplasty and/or stenting in diabetic patients is primarily
due to an exaggerated reactive intimal hyperplasia that
causes increased late lumen loss and decreased vessel lumen
area (13). In a recent pooled analysis of several major recent
stent trials, Cutlip et al. (14) found diabetes to be the
strongest clinical predictor for restenosis, with almost 50%
increased risk for target lesion revascularization at one-year
follow-up. Considering the higher rate of restenosis and the
current prevalence of diabetes among patients who undergo
PCI (e.g., a prevalence of 18% to 30% in most series), a
simple calculation would show that 30% to 40% of the
patients who sustain clinical restenosis and eventually un-
dergo target vessel revascularization are those with diabetes
mellitus. Thus, reduction of restenosis rate among diabetic
patients will have a major favorable impact on the global
outcome of catheter-based coronary interventions.
In this issue of the Journal, Corpus et al. (15) assessed the
effect of glycemic control on target vessel revascularization
at the time of coronary intervention among a group of 179
diabetic patients as compared with 60 non-diabetic control
patients. Patients who had optimal diabetic control, defined
as HbA1C7%, had a target vessel revascularization rate of
15%, compared with 34% among counterparts with a
HbA1C 7%. By multivariate analysis, poor glycemic
control, defined as a HbA1C 7%, was a major indepen-
dent predictor for target vessel revascularization with an
odds ratio  2.87. These results are in accord with a recent
study of 75 diabetic patients that identified poor glycemic
control as a significant predictor for angiographic restenosis
with an odds ratio 3.0 (16). Another important finding of
the current study is the observation of similar repeat
revascularization rates among both diabetic and non-
diabetic patients with optimal glycemic control.
The increased restenosis rate among patients with diabe-
tes has been attributed to various physiological mechanisms,
including accelerated neointimal responses, impaired vessel
remodeling, exaggerated thrombus formation, and persis-
tent endothelial dysfunction (17–19). Experimental models
have shown that the combination of hyperglycemia and
arterial injury induces expression of multiple inflammatory
cytokines that interact with the vessel wall to enhance
atherogenesis and/or neointimal formation by accelerating
smooth muscle proliferation (20,21). These observations are
in accord with animal and human studies suggesting that
arterial injury and accompanied inflammatory responses are
associated with exaggerated in-stent restenosis (22,23). It
has been thus hypothesized that pharmacologic interven-
tions aimed at improving glycemic control, via recovered
endothelial function, decreases in inflammatory responses,
and other yet-unrecognized mechanisms, may result in
reduced restenosis (24,25). An indirect support for the
potential benefit of optimal diabetic control may also be
derived from a recent report from the Diabetes Control and
Complications Trial (26). In this study that examined only
patients with type I diabetes, the progression of the intima-
media thickness of the carotid artery was significantly
reduced in the group that had received “intensive” compared
with the group receiving “conventional” hypoglycemic treat-
ment. Mean HbA1c levels were 7.2% and 9%, respectively,
and HbA1c level was found to be an independent predictor
for progression of intima-media thickness (26). Interest-
ingly, the differences between groups were noted at six years
but not at one-year follow-up, indicating a late effect (i.e.,
years rather than months) of diabetes control on macrovas-
cular complications. Progression of carotid intima-media
thickness was also associated with other risk factors such as
hypertension and elevated low-density lipoprotein (LDL)
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levels. Also, in a recent study, the degree of oxidative stress
and monocyte activation at a time of coronary intervention
was greater in patients with restenosis than in those without
restenosis and significantly correlated with the pre-
procedural levels of LDL (27). In the current study, hyper-
tension was more frequent, and the need for insulin was
twice as high among patients with elevated HbA1c levels
compared to normoglycemic patients, although LDL levels
were similar. It is possible that HbA1c, a marker for
glycosylation and/or glycemic control, may also mirror the
overall severity of diabetes by reflecting the overall risk
factor profile of the disease.
Several important issues are yet to be examined before
practical implications can be drawn concerning peri-
procedural optimal glycemic control. First, the study by
Corpus et al. does not establish a “dose response relation-
ship” between the levels of glycemic control and restenosis
prevention. In other words, it is unclear how strict glycemic
control should be and what is the optimal duration needed
to affect restenosis in the context of PCI. Second, because
the study population included mostly patients with Type II
diabetes, it is important to further examine whether a
similar beneficial effect will be obtained among patients with
Type I disease and/or those who are receiving long-term
insulin treatment. Moreover, a question still remains as to
whether post-procedural glycemic control also plays a role in
the process of restenosis. Unfortunately, HbA1c was not
recorded at follow-up, and currently no data are available to
address this question. The non-enzymatic process associ-
ated with the formation of advanced glycosylation end
products is complex and involves large numbers of proteins
and lipoproteins being exposed to hyperglycemia for months
to years. Thus, achieving optimal glycemic control might be
an impractical approach for most patients being referred for
coronary angiography and in need of an urgent revascular-
ization procedure. Nonetheless, the current study under-
scores the potential significance of an “aggressive” metabolic
normalization approach as part of a comprehensive thera-
peutic strategy aimed at inhibiting atherosclerotic progres-
sion and preventing restenosis among diabetic patients. This
approach should be evaluated in a large cohort of patients
wherein several preprocedural aggressive metabolic modifi-
cation strategies should be examined.
Finally, drug-eluting stents were recently introduced into
the clinical practice with most impressive effects on restenosis
prevention via local suppression of neointimal formation
(28,29). This approach may diminish the importance of
systemic optimization of glycemic control at the time of
coronary intervention for the purpose of restenosis prevention.
Nonetheless, the importance of a long-term comprehensive
therapeutic approach directed toward metabolic normalization
should be emphasized, using optimal glycemic control, ade-
quate lipid-lowering strategy, aggressive blood pressure man-
agement, and other risk-factor modification. Currently, those
therapeutic means may reduce the risk of long-term microvas-
cular and macrovascular complications among diabetic patients
regardless of restenosis prevention.
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